Application of CD271+ human bone marrow-derived: Stem cells for ischaemic heart disease therapy

Ali Ghodsizad; Mina Farag; Matthias Loebe; Eric Lumsden; Christoph Phiechaczek; Matthias Karck; Arjang Ruhparwar

doi:10.15420/ecr.2011.7.4.280

Application of CD271+ human bone marrow-derived: Stem cells for ischaemic heart disease therapy

Ali Ghodsizad, Mina Farag, Matthias Loebe, Eric Lumsden, Christoph Phiechaczek, Matthias Karck, Arjang Ruhparwar

Academic Institute

Research output: Contribution to journal › Article › peer-review

Abstract

Cell transplantation for myocardial regeneration has been shown to have beneficial effects on cardiac function after myocardial infarction. Here, we discuss the application of CD 271+ bone marrow-derived stem cells (BMCs) as novel markers for the enrichment of mesenchymal somatic stem cells. Injection of BMCs into ischaemic myocardium during surgery has been shown to be both feasible and safe. This novel approach might hold promise as an alternative to medical management in patients with severe ischaemic heart failure who are ineligible for conventional revascularisation.

Original language	English (US)
Pages (from-to)	280-282
Number of pages	3
Journal	European Cardiology
Volume	7
Issue number	4
DOIs	https://doi.org/10.15420/ecr.2011.7.4.280
State	Published - Jun 2011

Keywords

Bone marrow-derived stem cells
CD 271+
Ischaemic heart disease
Somatic stem cells
Stem cell therapy

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.15420/ecr.2011.7.4.280

Cite this

@article{e99509e265e8417186d9f68d61c7592f,

title = "Application of CD271+ human bone marrow-derived: Stem cells for ischaemic heart disease therapy",

abstract = "Cell transplantation for myocardial regeneration has been shown to have beneficial effects on cardiac function after myocardial infarction. Here, we discuss the application of CD 271+ bone marrow-derived stem cells (BMCs) as novel markers for the enrichment of mesenchymal somatic stem cells. Injection of BMCs into ischaemic myocardium during surgery has been shown to be both feasible and safe. This novel approach might hold promise as an alternative to medical management in patients with severe ischaemic heart failure who are ineligible for conventional revascularisation.",

keywords = "Bone marrow-derived stem cells, CD 271+, Ischaemic heart disease, Somatic stem cells, Stem cell therapy",

author = "Ali Ghodsizad and Mina Farag and Matthias Loebe and Eric Lumsden and Christoph Phiechaczek and Matthias Karck and Arjang Ruhparwar",

year = "2011",

month = jun,

doi = "10.15420/ecr.2011.7.4.280",

language = "English (US)",

volume = "7",

pages = "280--282",

journal = "European Cardiology",

issn = "1758-3756",

publisher = "Radcliffe Medical Media",

number = "4",

}

TY - JOUR

T1 - Application of CD271+ human bone marrow-derived

T2 - Stem cells for ischaemic heart disease therapy

AU - Ghodsizad, Ali

AU - Farag, Mina

AU - Loebe, Matthias

AU - Lumsden, Eric

AU - Phiechaczek, Christoph

AU - Karck, Matthias

AU - Ruhparwar, Arjang

PY - 2011/6

Y1 - 2011/6

N2 - Cell transplantation for myocardial regeneration has been shown to have beneficial effects on cardiac function after myocardial infarction. Here, we discuss the application of CD 271+ bone marrow-derived stem cells (BMCs) as novel markers for the enrichment of mesenchymal somatic stem cells. Injection of BMCs into ischaemic myocardium during surgery has been shown to be both feasible and safe. This novel approach might hold promise as an alternative to medical management in patients with severe ischaemic heart failure who are ineligible for conventional revascularisation.

AB - Cell transplantation for myocardial regeneration has been shown to have beneficial effects on cardiac function after myocardial infarction. Here, we discuss the application of CD 271+ bone marrow-derived stem cells (BMCs) as novel markers for the enrichment of mesenchymal somatic stem cells. Injection of BMCs into ischaemic myocardium during surgery has been shown to be both feasible and safe. This novel approach might hold promise as an alternative to medical management in patients with severe ischaemic heart failure who are ineligible for conventional revascularisation.

KW - Bone marrow-derived stem cells

KW - CD 271+

KW - Ischaemic heart disease

KW - Somatic stem cells

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=84856112998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856112998&partnerID=8YFLogxK

U2 - 10.15420/ecr.2011.7.4.280

DO - 10.15420/ecr.2011.7.4.280

M3 - Article

AN - SCOPUS:84856112998

SN - 1758-3756

VL - 7

SP - 280

EP - 282

JO - European Cardiology

JF - European Cardiology

IS - 4

ER -

Application of CD271+ human bone marrow-derived: Stem cells for ischaemic heart disease therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this